AQR Capital Management LLC Makes New Investment in Zura Bio Limited (NASDAQ:ZURA)

AQR Capital Management LLC bought a new stake in Zura Bio Limited (NASDAQ:ZURA) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 12,319 shares of the company’s stock, valued at approximately $43,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZURA. Armistice Capital LLC boosted its stake in Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after buying an additional 876,000 shares during the last quarter. Great Point Partners LLC increased its position in Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after purchasing an additional 1,884,501 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after buying an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after buying an additional 6,412 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new position in Zura Bio in the first quarter valued at approximately $1,157,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Trading Up 0.6 %

Shares of ZURA opened at $4.92 on Friday. Zura Bio Limited has a 52-week low of $2.00 and a 52-week high of $6.35. The company has a 50-day simple moving average of $3.92 and a 200-day simple moving average of $3.96.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, research analysts anticipate that Zura Bio Limited will post -0.47 EPS for the current year.

Insider Activity at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 15.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZURA. Piper Sandler reissued an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Friday. Finally, HC Wainwright started coverage on Zura Bio in a research report on Thursday, September 5th. They issued a “neutral” rating and a $5.00 price target on the stock.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.